Nonalcoholic fatty liver disease is a spectrum of liver disease ranging from simple hepatic steatosis to steatohepatitis, hepatic fibrosis, and cirrhosis. It is highly associated with obesity and insulin resistance, and with the dramatic increase in childhood and adolescent obesity, it has become the most common form of chronic liver disease in these age groups. Genetic and environmental factors both appear to play a role in the development of nonalcoholic fatty liver disease. There is currently no established effective therapy, and decreasing the prevalence of this disorder will require a reduction in the current obesity epidemic.
DanielsSR. Complications of obesity in children and adolescents. Int J Obes. 2009;33:s60-s65.
2.
BrowningJDSzczepaniakLSDobbinsR. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395.
3.
ClarkJMBrancatiFLDiehlAM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960-967.
4.
StraussRSBarlowSEDietzWH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr. 2000;136:727-733.
5.
SchwimmerJBDeutschRKahenT. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388-1393.
6.
MoranAJacobsDRJrSteinbergerJ. Changes in insulin resistance and cardiovascular risk during adolescence: establishment of differential risk in males and females. Circulation. 2008;117:2361-2368.
7.
RomeoSKozlitinaJXingC. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461-1465.
8.
SantoroNKursaweRD’AdamoE. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology. 2010;52:1281-1290.
9.
PaganoCSoardoGEspositoW. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 2005;152:113-118.
10.
PattonHMLavineJEVan NattaML. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology. 2008;135:1961-1971.
11.
VosMBBarvSJoshi-BarveS. Cytokeratin 18, as a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2008;47:481-485.
12.
SchwimmerJBBehlingCNewburyR. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42:641-649.
13.
NobiliVMancoMRaponiM. Case management in children affected by non-alcoholic fatty liver disease. J Paediatr Child Health. 2007;43:414.
14.
DavisJNLeKAWalkerRW. Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr. 2010;92:1522-1527.
15.
LavineJE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000;136:734-738.
16.
SanyalAJChalasaniNKowdleyKV. Pioglitazone, vitamin E or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-1685.
17.
LavineJESchwimmerJBVan NattaML. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents. JAMA. 2011;305:1659-1668.
18.
VajroPFranzeseAValerioG. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr. 2000;136:739-743.
